Analysis of countries where linezolid is banned and the reasons

As of now, linezolid (Linezolid) has not been completely banned in major countries, but in some areas, its use is subject to strict restrictions or special warnings. This is mainly due to the risk of some serious side effects of linezolid itself and the problem of drug resistance. Linezolid, as a synthetic antibacterial drug for both oral and intravenous injection, belongs to the oxazolidinone antibiotics and is effective against a variety of gram-positive bacterial infections, especially against multi-drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

However, because of its potency, long-term use of linezolid can lead to serious adverse effects, including myelosuppression (such as anemia, leukopenia, and thrombocytopenia), peripheral neuropathy, and optic neuropathy. In some cases, especially after treatment for more than 28 days, the incidence of these side effects increases significantly, and some of the damage may be irreversible. In addition, linezolid inhibits monoamine oxidase (MAO), which may cause hypertensive crisis or serotonin syndrome when combined with certain drugs or foods (such as foods high in tyramine).

Due to public health and safety considerations, some countries and regions have adopted an extremely cautious attitude towards the use of linezolid, such as requiring its use in strict hospital settings, or limiting its use to second- or third-line drugs only when other drugs are ineffective. This is particularly evident in some countries in Europe (such as Germany and Switzerland) and parts of Asia (such as Japan).

In addition, although the U.S. FDA and the European Medicines Agency (EMA) have not banned the sale of linezolid, they have issued black box warnings on its use and require enhanced blood monitoring during medication. It can be said that linezolid was not banned because of efficacy issues, but because its potential risks require strict medical management and standardized application.

Reference materials:https://go.drugbank.com/drugs/DB00601